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The human microbiota is an aggregate of microorganisms residing in the human body, mostly in the 
gastrointestinal tract (GIT). Our gut microbiota evolves with us and plays a pivotal role in human health 
and disease. In recent years, the microbiota has gained increasing attention due to its impact on host 
metabolism, physiology, and immune system development, but also because the perturbation of the 
microbiota may result in a number of diseases. The gut microbiota may be linked to malignancies such 
as gastric cancer and colorectal cancer. It may also be linked to disorders such as nonalcoholic fatty liver 
disease (NAFLD); obesity and diabetes, which are characterized as “lifestyle diseases” of the industrial-
ized world; coronary heart disease; and neurological disorders. Although the revolution in molecular 
technologies has provided us with the necessary tools to study the gut microbiota more accurately, we 
need to elucidate the relationships between the gut microbiota and several human pathologies more 
precisely, as understanding the impact that the microbiota plays in various diseases is fundamental for 
the development of novel therapeutic strategies. Therefore, the aim of this review is to provide the read-
er with an updated overview of the importance of the gut microbiota for human health and the poten-
tial to manipulate gut microbial composition for purposes such as the treatment of antibiotic-resistant 
Clostridium difficile (C. difficile) infections. The concept of altering the gut community by microbial inter-
vention in an effort to improve health is currently in its infancy. However, the therapeutic implications 
appear to be very great. Thus, the removal of harmful organisms and the enrichment of beneficial mi-
crobes may protect our health, and such efforts will pave the way for the development of more rational 
treatment options in the future. 
© 2017 THE AUTHORS. Published by Elsevier LTD on behalf of the Chinese Academy of Engineering and 
Higher Education Press Limited Company. This is an open access article under the CC BY-NC-ND 
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Trillions of gut microbes reside in the human body, primarily 
within the gastrointestinal tract (GIT), where the population of gut 
microbes increases by approximately eight orders of magnitude 
from the proximal small intestine (103 mL–1 luminal content) to 
the colon (1011 g–1 content) [1]. Taking a 70 kg man as a reference, 
the total number of microbes is estimated to be 3.8 × 1013, with 
a total weight of 0.2 kg [2]. Metagenomics sequencing is able to 
detect more than 1000 species of gut microbes, which are domi-
nated by four major phyla: Firmicutes, Bacteroidetes, Actinobac-
teria, and Proteobacteria. The genomes of these microbes encom-
pass more than three million genes—approximately 100 times 
more than the entire human genome [3]. These gut microbes are 
acquired as early as during fetal development, and there is grow-
ing evidence for the presence of gut microbes in the placenta, 
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amniotic fluid, and meconium [4–7]. Although gut microbes are 
phylogenetically conserved [8], the composition of human gut 
microbes can be affected by the host’s personal hygiene, diet, 
drug intake, and disease status throughout his or her life [9,10]. 
These effects are more profound during the early life stages, when 
initial microbial colonization begins; however, the stability and 
homeostasis of gut microbes are usually established once the host 
is between 2–5 years of age [11].
In recent years, gut microbes have been gaining increasing 
attention due to their impact on human health [12]. The composi-
tion and function of our gut microbes appear to play an essential 
role in almost every biological process in the body. It has long 
been recognized that gut microbes can help their host to defend 
against pathogens, develop a healthy intestinal structure and im-
mune system, and aid with the digestion of indigestible dietary 
fibers [13]. More recently, associations have also been recognized 
between gut microbes and diseases such as fatty liver disease, 
coronary heart disease, cancer, and obesity and diabetes [14]. In 
this review, we summarize and provide the most recent facts on 
the roles of gut microbes in human health, along with the unmet 
need for and solutions toward modulating the gut microbiota.
2. The function of gut microbes in human health
Gut microbes can coexist symbiotically with a healthy human. 
Short-chain fatty acids (SCFAs), including butyrate, acetate, and 
propionate, are fermentation products of dietary fibers produced 
by gut microbes. Although such fibers are otherwise indigestible 
by humans, their metabolites provide essential nutrients for co-
lonic cells and play an important role in maintaining gut health. 
Eubacterium hallii (E. hallii) is considered to be an SCFA-producing 
microbe, and a recent discovery indicates that E. hallii is capable 
of producing high levels of glycerol/diol dehydratase, a key en-
zyme in the conversion of glycerol to 3-hydroxypropionaldehyde, 
a process that also produces cobalamin [15]. Levels of serotonin, 
a neurotransmitter synthesized in colonic enterochromaffin cells 
that is known to regulate a wide range of physiological activities 
such as enteric motor and platelet function, are regulated by the 
ingestion of spore-forming bacteria, mainly consisting of clostrid-
ial species [16]. Other studies have also investigated the relation-
ship between gut microbes and gut metabolites.
Gut microbes are thought to metabolize phenyl-containing 
amino acids, such as tryptophan. Levels of tryptophan metab-
olites, such as indoxyl sulfate and indole-3-propionic acid, are 
highly correlated to the presence of gut microbes [17]. The pro-
duction of indole-3-propionic acid is dependent on the coloniza-
tion of the bacterium Clostridium sporogenes [17]. Furthermore, 
variations in Faecalibacterium prausnitzii colonies have been as-
sociated with levels of urinary metabolites involved in multiple 
metabolic pathways [18]. One such association has been identi-
fied between Clostridium difficile (C. difficile) and levels of fecal 
cholesterol and coprostanol, indicating that gut microbes play a 
crucial role in lipid metabolism [19]. Taken together, these stud-
ies highlight the essential role of gut microbes in maintaining 
normal physiology in humans. A deviation from the normal gut 
ecosystem could therefore be associated with a range of abnor-
malities, such as cancer, nonalcoholic fatty liver disease (NAFLD), 
obesity and diabetes, coronary heart disease, kidney dysfunction, 
and neurodegenerative diseases (Fig. 1); these associations will 
be summarized in the forthcoming sections.
2.1. Cancer
Levels of Helicobacter pylori are widely associated with an 
increased risk of gastric [20] and colorectal cancer [21]. A Gram-
negative bacterium resides in the human stomach and can cause 
various diseases including gastritis, peptic ulcer, and gastric can-
cer [21]. Other resident gut microbes have also been identified as 
major factors in the increased risk of human colon cancer, includ-
ing Streptococcus bovis [22,23], Bacteroides fragilis [24], and Es-
cherichia coli (E. coli) [25]. These bacteria can cause inflammation 
and may trigger inflammatory bowel disease, thereby promoting 
the development of colorectal cancer. The proposed mechanism 
for this increased risk is recognized as involving Toll-like recep-
tors (TLRs) and triggering downstream signaling pathways such 
as NF-κB, ERK, JNK, and p38, leading to an up-regulation of the 
growth factors and inflammatory mediators that promote neopla-
sia [26].
2.2. Nonalcoholic fatty liver disease
NAFLD is the most common chronic liver condition in both 
Western [27] and Asian [28] countries, and is considered to be 
a hepatic manifestation of metabolic syndrome. Due to its close 
link with obesity, the pathogenesis of NAFLD has been widely 
accepted to be the result of multiple “hits,” including the contri-
bution of the intestinal dysbiosis that is associated with obesity 
[29,30].
Studies show that a shift in the gut microbe composition is as-
sociated with obesity, and correlates closely with the prevalence 
and progress of NAFLD [31–34]. Zhu et al. [34] have suggested 
that the connection between gut-derived endogenous alcoholic 
and nonalcoholic steatohepatitis (NASH) might be involved in the 
pathogenesis of obesity in children. A significant compositional 
shift in gut microbes, such as the decrease of some selected mem-
bers of Firmicutes, has been observed in patients with NAFLD 
[33]. A decrease in Bacteroidetes has also been found among 
obese patients with NASH compared with healthy controls [34]. 
In addition, Wang et al. [30] assessed the fecal microbial composi-
tion and its correlation with liver biochemistry in non-obese adult 
patients with NAFLD. Boursier et al. [35] have suggested that the 
severity of NAFLD is associated with gut dysbiosis along with a 
shift in metabolic function of the gut microbiota. Boursier et al. [35] 
also revealed that Bacteroides and Ruminococcus are independently 
associated with NASH and significant fibrosis, respectively. These 
studies indicate that an alteration in the composition of the gut 
microbiota is closely associated with the development of NAFLD.
Several different mechanisms have been uncovered that relate 
to gut microbe composition and the pathogenesis of NAFLD. Firstly, 
gut microbes have the potential to increase energy extraction 
from ingested food [36]; alter appetite signaling [37,38]; and 
enhance the expression of genes involved in de novo lipogene-
sis, β-oxidation, or inflammation-driven liver steatosis [39,40]. 
Secondly, gut microbes and the translocation of gut-derived 
bacteria or metabolites are likely to influence the development of 
hepatic inflammation [41,42]. Small intestinal bacterial overgrowth 
Fig.1. Summary of the role of gut microbes and their modulation in a pathological 
state.
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ping them from being converted into fat for deposition. Another 
important function of gut microbes is the modulation of lipid ab-
sorption. This process is achieved via the action of gut microbes 
that are capable of removing polar groups of glycine and taurine 
from bile acids, leading to less fat being emulsified and absorbed 
from the GIT. De-conjugated bile acids are therefore absorbed by 
the host, affecting cholesterol metabolism [57,58]. Kishino et al. 
[59] identified genes in the gut bacterium Lactobacillus plantarum 
that encode for the enzymes involved in the saturation metabo-
lism of polyunsaturated fatty acids.
2.4. Coronary heart disease
Gut microbes associated with obesity and T2D may promote 
coronary heart disease. In addition, bacterial DNA is found in 
human atherosclerotic samples; to be specific, Chryseomonas is 
present in human atherosclerotic samples, and Veillonella and 
Streptococcus are found in the majority of atherosclerotic sam-
ples, as well as in the oral cavity and gut of the same patients [60]. 
This evidence indicates that the presence of these gut microbes 
correlates directly with coronary heart disease. Another popula-
tion study involving 893 participants constructed a novel model 
demonstrating that 26% of high-density lipoproteins are attrib-
uted to the gut microbiome, independent of age, sex, and host 
genetics [61]. Gut microbes modulating lipid metabolism and 
cholesterol via bile acids provide a possible mechanism for the 
relationship between gut microbes and coronary heart disease. 
A link between coronary heart disease and the microbial metab-
olism of dietary choline and L-carnitine has already been estab-
lished [62,63]. Both choline and L-carnitine can be metabolized 
by gut microbes, producing trimethylamine (TMA), which is then 
further metabolized in the liver into trimethylamine-N-oxide 
(TMAO). TMAO has been recognized as a pro-atherogenic agent 
[64]. The underlying mechanism that describes the association 
between TMAO-producing gut microbes and coronary heart dis-
ease is attributed to the action of a TMAO-producing enzyme, 
flavin monooxygenase-3, which is involved in the perturbations 
of reverse cholesterol transport and which has the effect of reor-
ganizing the total cholesterol balance of the body [65,66]. Further 
evidence has shown that targeting the gut microbial production 
of TMA with a non-lethal microbial inhibitor, 3,3-dimethyl-1- 
butanol, could reduce the levels of TMAO and prevent atheroscle-
rotic lesion [67].
2.5. Neurodegenerative diseases
Increasing evidence is revealing the involvement of gut mi-
crobes in modulating neurological diseases via a bidirectional 
microbiota-gut-brain axis [68]. In experiments, germ-free mice 
exhibited increased motor activity and reduced anxiety-like be-
havior compared with conventional specific pathogen-free mice 
[69]. The germ-free mice also expressed lower mRNA levels of 
hippocampal serotonin 1A receptor and amygdala N-methyl-D- 
aspartate receptor (NMDAR) subunit NR2B [70], and higher levels 
of the brain-derived neurotrophic factor (BDNF) in the dentate 
granule layer of the hippocampus [70]. Other studies have found 
that colonization with Clostridium butyricum can restore cogni-
tive defects [71]. Administration of Lactobacillus farciminis [72], 
Lactobacillus reuteri [73], Bacteroides fragilis [74], or Lactobacillus 
rhamnosus strains [75,76] could also potentially prevent stress- 
induced social deficit and reduce the levels of stress-induced plas-
ma corticosterone in mice [76], suggesting that the gut microflora 
could be a potential therapeutic target for neurodegenerative 
diseases. This result was verified by Möhle et al. [77], who used a 
broad spectrum of antibiotics (such as ampicillin and vancomycin) 
syndrome (SIBOS) is highly prevalent in patients with NAFLD [43], 
which appears to be related to an increased gut permeability in 
these patients [44]. Intestinal permeability plays an important 
role in the pathogenesis of NAFLD, which in turn leads to hepato-
cellular inflammation [44,45] and insulin resistance [32,39]. It is 
notable that the expression levels of the lipopolysaccharide (LPS) 
receptor, CD14, and of TLR-4 are also higher in NASH patients with 
SIBOS [46]. This finding suggests that SIBOS, and particularly its 
Gram-negative bacteria population, promotes the progression of 
NASH through TLR-4. Research has indicated that an up-regulation 
of CD14 in Kupffer cells is related to a hepatic hyper-inflammatory 
response to LPS during NASH progression [47].
2.3. Obesity and diabetes
A large body of evidence from both population and animal 
studies indicates that alterations in the gut microbe composi-
tion are associated with obesity and type II diabetes (T2D). For 
example, Bäckhed et al. [48] showed that wild-type mice gained 
40% more body weight than germ-free mice, although germ-free 
mice consumed 29% more food, while re-conventionalized germ-
free mice gained 57% in body weight. This observation led to in-
creased interest in investigating the composition of gut microbes 
in obese mice. Studies have shown that microbe composition in 
obese mice (ob/ob) is reduced by 50% in the presence of high lev-
els of Bacteroidetes and Firmicutes, as compared with that in cor-
responding lean mice [49]. Further evidence revealed that diet- 
induced obesity may produce rich levels of Firmicutes, specifi-
cally in the Mollicutes class. In addition, lean germ-free mice re-
ceiving gut microbes from diet-induced obese mice have more fat 
depositions than those receiving from lean donors [50]. The effect 
of lean-like gut microbe transplantation is equally significant for 
obese mice when they are co-housed with lean mice, with the 
composition of the gut microbes of obese mice containing more 
Bacteroidetes when such mice are co-housed with lean mice [51].
Population studies have also highlighted the association be-
tween gut microbe composition and obesity. Turnbaugh et al. 
[50] showed that human obesity was associated with altera-
tions in levels of Bacteroidetes and Firmicutes. It is notable that 
obesity-associated microbes from humans can be transferred to 
germ-free mice, resulting in significantly increased body fat as 
compared with germ-free mice colonized with lean microbes 
[36]. The transferable colonization of fat- or lean-associated 
microbes has been confirmed by Zhang and coworkers [52]. 
Obese children and/or children predisposed to obesity, such 
as those with Prader-Willi syndrome, are subjected to a diet 
rich in non-digestible carbohydrates in order to induce weight 
loss [53]. Germ-free mice colonized with pre-intervention gut 
microbes showed larger body fat accumulation as compared 
with mice with post-intervention gut microbes [52]. Altera-
tions of gut microbe composition are also associated with T2D 
[54]. An overall decrease in proportions of phylum Firmicutes 
and class Clostridia is presented in diabetic patients, which is 
in contrast to gut microbes found in obese patients [55]. In ad-
dition, Clostridium species and Lactobacillus species appear to 
be important in driving T2D [56]. The range of SCFA-producing 
bacteria is low in the diabetic population as compared with a 
healthy background population [3].
The link between gut microbe composition and obesity is 
believed to be mediated by the metabolic function of the gut mi-
crobes. That is, gut microbes produce SCFAs, which provide essen-
tial nutrients and energy for maintaining a healthy and intact gut 
barrier. Without these gut microbes, the GIT becomes defective, 
possibly due to the lack of essential SCFAs. Such a defective gut 
structure may inhibit the delivery of nutrients to the liver, stop-
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to treat adult mice with neurodegenerative diseases. Their study 
concluded that antibiotic treatment decreased hippocampal neuro-
genesis and memory retention from neuronal progenitors, and that 
recognition tests were affected. These deficits were, however, fully 
restored in mice fed with a mixture of eight probiotics, namely 
Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium 
longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactoba-
cillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii 
subsp. bulgaricus [77]. It is notable that all of these probiotic mod-
ulations were similar in vagotomized mice, demonstrating that the 
vagus is a major modulatory constitutive communication pathway 
in connecting bacteria, gut, and brain [76].
Neuroinflammation is likely to be closely linked with multi-
ple neurodegenerative pathways involved in neurodegenerative 
diseases [78]. The compositions of fecal microbiota from patients 
with Parkinson’s disease exhibited decreased “anti-inflammatory” 
butyrate-producing bacteria, such as Blautia, Coprococcus, and 
Roseburia, whereas the mucosal microbiota displayed reduced 
levels of Faecalibacterium [79]. Such colonic dysbiosis with a 
lower abundance of fecal E. coli and Butyrivibrio fibrisolvens was 
also reported in an amyotrophic lateral sclerosis mouse model 
[80], implying that bacteria may play a crucial role in the neu-
roinflammation of neurodegenerative diseases. More evidence 
for the presence of a gut-brain axis comes from studies on the 
modulation of gut microbes on neurotransmitters. Barrett et 
al. [81] revealed that microaerophilic Lactobacillus and Bifido-
bacterium species were capable of metabolizing glutamate into 
gamma amino butyric acid (GABA). Furthermore, Cyanobacteria 
have been reported to produce neurotoxins such as β-N-methyl-
amino-L-alanine (BMAA) that contribute to various neurological 
dysfunctions [82].
3. Modulation of gut microbes
3.1. Dietary modulation of gut microbe composition
Gut microbes are increasingly being recognized as a forgotten 
“organ” that plays a crucial role in disease development. Ques-
tions remain as to how microbes can be manipulated in order 
to maintain good health. Food intake appears to be the first 
treatment of choice in modulating gut microbes. Amato et al. 
[83] showed that a Western diet may result in increased levels 
of Firmicutes and reduced levels of Prevotella, which are both 
associated with obesity and T2D. In animal models, levels of Fir-
micutes and Bacteroidetes are closely associated with a high-fat 
diet [84]. Four weeks of continuous intake of a high-fat diet has 
been shown to induce an increased abundance of Firmicutes and 
a decreased abundance of Tenericutes. Reduced levels of Bacte-
roidetes occur after eight weeks of continuous intake of a high-fat 
diet [84]. Modification of the resulting unhealthy gut, using a veg-
etarian diet or probiotics, may be achieved by providing nutrients 
that are favored by some bacteria groups, such as Prevotella [85]. 
Interventions with four days of a meat-based or vegetable-based 
diet have been shown to change the composition of gut microbes 
extensively. For example, an increased abundance of bacteria 
involved in amino acid fermentation, such as Alistipes putredinis, 
Bilophila, and Bacteroides, is associated with a meat-based diet, 
whereas bacteria involved in carbohydrate fermentation, such as 
Roseburia, Eubacterium rectale, Ruminococcus bromii, and Faecali-
bacterium prausnitzii, are associated with a vegetable-based diet 
[85]. Recent studies into the correlations between gut microbes 
and 126 exogenous and intrinsic host factors, such as disease 
states and dietary factors, have identified a positive correlation 
between a high-carbohydrate diet and high levels of Bifidobac-
teria, but a negative correlation between a high-carbohydrate 
diet and Lactobacillus, Streptococcus, and Roseburia species [86]. 
Furthermore, red wine consumption is associated with increased 
levels of Faecalibacterium prausnitzii, which is known to have an 
anti-inflammatory effect [87].
Prebiotics, such as dietary fibers and some oligosaccharides, 
have been shown to have beneficial effects on human health [88]. 
Changes in gut microbes as sociated with ingestion of prebiotics 
have been widely reported. For example, a 10-fold increase in fe-
cal Bifidobacteria has been demonstrated in people who have re-
ceived oligosaccharides intervention as compared with a placebo 
control group [89,90]. Furthermore, probiotics supplementation 
appears to be more effective in infants than in adults [91], a result 
that is largely due to the gut microbial community, which may 
have a greater impact on infants since it is under development at 
that age, resulting in a more easily manipulated effect. Thus, an 
increased abundance of Lactobacillaceae and Bifidobacteriaceae 
species has been found in children supplemented with Lactoba-
cillus rhamnosus GG (LGG) [92]. In addition, LGG supplementation 
induces increased levels of Lactococcus and Lactobacillus, along 
with a decrease in E. coli in pre-school children [93].
3.2. Drugs modulate gut microbe composition
Antibiotic treatment is used to treat pathogenic infections, and 
is shown to have profound effects on the gut microbiota. Zhao 
et al. [94] reported that treating mice with gentamicin and cef-
triaxone induces decreased levels of Barnesiella, Prevotella, and 
Alistipes, albeit with increased levels of Bacteroides, Enterococcus, 
Erysipelotrichaceae incertae sedis, and Mycoplasma. In addition, 
mouse models have shown that this treatment can cause a de-
crease in a range of metabolites, including SCFAs, amino acids, 
and primary bile acid, and an increase in oligosaccharides, cho-
line, and secondary bile acids [94].
Responses to antibiotic treatment vary between individuals. 
Analyses of gut microbes over a 10-month period of three indi-
viduals who received two courses of ciprofloxacin suggest that 
the gut microbial community is relatively stable and has limited 
day-to-day variability, and that large inter-person variations are 
prominent in the gut microbial community [95]. Moreover, anti-
biotic treatment results in a rapid shift of the gut microbial com-
munity during the course of the treatment, mainly manifested as 
a loss of microbial diversity. Despite the recovery in the levels of 
major microbial colonies after a week of antibiotic withdrawal, 
these levels are not fully restored [95]. This finding reveals that 
the gut community is resistant to changes unless it experiences 
repeated perturbations in the long term. Many herbal medicines 
are rich in polyphenols, which must interact with gut microbes in 
order to become bioavailable and bioactive [96], and which could 
modulate the gut microbial community. In addition, herbal med-
icines often exert mild anti-bacterial effects [97] and, if used over 
a long-term period, may permanently modulate the gut microbial 
community. Thus, there is a huge potential for managing diseases 
through the modulation of gut microbes.
3.3. Fecal transplantation modulates gut microbe composition
The first description of a fecal microbiota-transplantation (FMT) 
in the treatment of C. difficile occurred in 1958 [98]. There has been a 
recent increase in the use of fecal transplantation for modulating 
the gut microbial community and eliminating C. difficile colonies. 
Fecal transplantation treatment for C. difficile appears to be effec-
tive: 81% of C. difficile infection cases were resolved after the first 
FMT treatment [99]. This result has been reproduced in a clinical 
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trial of 232 Canadian patients infected with C. difficile, showing 
that stool preparation methods (freshly prepared vs. frozen) actu-
ally had no effect on the outcome of the significance in altering the 
gut microbial community [100]. This observation demonstrates the 
benefit of a frozen sample preparation, in which safety measures 
could be put in place prior to the treatment of patients. The gut mi-
crobial communities of donors and their respective recipients are 
closely correlated soon after the transplantation, but may deviate 
from each other over time. Thus, populations of Bacteroidetes and 
Firmicutes in FMT recipients have been shown to increase to levels 
that are equivalent to those of fecal donors, whereas the levels of 
C. difficile have been shown to decrease from 4% to 0.2% in FMT re-
cipients [99]. Other microbial alterations have also been associated 
with fecal transplantation, including the shift from Proteobacteria 
to Firmicutes and Bacteroidetes dominant species [101–103]. Given 
the stability of the gut microbial community [95], it may be impor-
tant for patients infected with C. difficile to receive multiple fecal 
transplantations in order to establish a healthy microbial system 
over the long term.
4. Future perspectives
This review covered some typical studies on the association 
between gut microbes and various disease states as well as meth-
ods to modulate the composition of gut microbes. It is not our in-
tention to be comprehensive, but rather to highlight some recent 
and outstanding research publications. At this point, it is evident 
that gut microbes have a considerable impact on human health. 
Research has revealed that the gut microbial community may 
be modulated by various methods, such as food, drugs, and fecal 
transplantation. It has accordingly become necessary to define 
the microbial composition of a healthy gut, and to learn how in-
dividual characteristics (age, gender, and ethnicity) may affect the 
composition of the gut microbiota. Given the intrinsic stability of 
our gut microbial community, long-term interventional follow-up 
may become necessary as well.
However, more insight is needed into the mechanisms of the 
action of gut microbes, which are often mediated by metabolites 
such as bile acids, SCFAs, and choline. The specific microbes re-
sponsible for such actions still remain unclear, but are necessary 
for specific gut microbial modulation. Despite extensive research 
into correlations between levels of metabolites and specific gut 
microbes [18], the causative factor of gut microbes in various 
diseases is not yet clarified. Therefore, investigating these under-
lying molecular mechanisms remains as an important focus in 
future research, and will require concerted efforts from scholars 
in multidisciplinary areas of research, including clinical doctors, 
microbiologists, molecular biologists, and biological chemists. 
Finally, novel emerging research on the role of gut microbes in 
neurodegenerative diseases presents an area of especially unmet 
need; particular attention is required on how gut microbes and 
their metabolites can access the brain and affect various neuro-
logical functions in humans.
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